KNIGHT THERAPEUTICS INC.

Management's Discussion and Analysis

For the three and nine-month periods ended September 30, 2024

TABLE OF CONTENTS

The following is Management's Discussion and Analysis of the financial condition and operating results of Knight Therapeutics Inc. ("Knight" or the "Company") for the three and nine-month periods ended September 30, 2024. This document should be read in conjunction with the unaudited interim condensed consolidated financial statements and notes thereto for the three and nine-month periods ended September 30, 2024, and the audited consolidated financial statements and Management's Discussion and Analysis of financial condition and operating results in our annual report for the year ended December 31, 2023. Knight's unaudited interim condensed consolidated financial statements as at and for the three and nine-month periods ended September 30, 2024, have been prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting".

All amounts herein are expressed in thousands of Canadian dollars (unless otherwise indicated) except for share and per share amounts. All other currencies are in thousands. All positive variance represent a positive impact to net income (loss) and a negative variance represents a negative impact to net income . All percentage changes are presented in absolute values.

For a glossary of abbreviations used throughout this MD&A refer to section Glossary of Abbreviations.

This discussion and analysis were prepared by management from information available as of November 6, 2024. Further information about Knight Therapeutics Inc., including the Annual Information Form, is available online on SEDAR+ at www.sedarplus.ca.

Cautionary note regarding forward-looking statements

This Management's Discussion and Analysis may contain certain "forward-looking statements" and certain "forward-looking information" as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "continue", "plans" or similar terminology. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company's actual results, performance, or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. Factors and risks which could cause actual results to differ materially from current expectations are discussed in the Company's Annual Report and in the Company's latest Annual Information Form found on SEDAR at www.sedarplus.ca. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management's best judgment based on the information currently available. No forward-looking statement can be guaranteed, and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

OVERVIEW

Section 1 – About Knight Therapeutics Inc.

Knight Therapeutics Inc. is a specialty pharmaceutical company, headquartered in Montreal, Canada, and listed on the Toronto Stock Exchange under the ticker symbol "GUD". The Company operates in Canada, Latin America and select international markets and the activities performed are as follows:

- Principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets.
- Finances other life sciences companies with the goal of strengthening relationships in the life science industry and securing product distribution rights for Canada and select international markets.
- Invested in life sciences venture capital funds whereby the Company may receive preferential access to innovative healthcare products for Canada and select international markets.
- Develops innovative pharmaceutical products including those to treat neglected tropical and rare pediatric diseases.

Section 2 – Q3-24 Highlights

Financial Results

- Revenues of $92,263, an increase of $10,763 or 13% or $13,801 or 18% on a constant currency[1] basis over the same period in the prior year. The increase is driven by the growth of our key promoted products partly offset by declines of our mature products.
- Gross margin of $45,017 or 49% of revenues compared to $40,182 or 49% of revenues in the same period in the prior year.
- Adjusted EBITDA[1] was $13,454, a decrease of $2,058 or 13% over the same period in the prior year.
- Adjusted EBITDA per share[1] of $0.13, a decrease of $0.02 or 10% over the same period in the prior year driven by investments on our new launches and pipeline.
- Net income was $85, compared to $9,588 in the same period in the prior year.
- Cash inflow from operations was $5,016, compared to $15,166 in the same period in the prior year.

Corporate Developments

- Purchased 437,500 common shares through Knight's NCIB at an average price of $5.65 for an aggregate cash consideration of $2,474.

Subsequent to quarter-end

- Obtained regulatory approval for Minjuvi® (tafasitamab) in Mexico.
- Recorded an unrealized gain of $14,412 recognized in other comprehensive income in Q3-24 on our shares of Synergy driven by its IPO in October 2024.

[1] *Adjusted EBITDA, Adjusted EBITDA per share and revenues at constant currency are non-GAAP measures. Refer to section 15 - Non-GAAP measures for additional details.*

(In thousands of Canadian dollars, except for share and per share amounts)

FINANCIAL RESULTS

Section 3 – Results of Operations

Hyperinflation

The Company applies IAS 29, Financial Reporting in Hyperinflation Economies, as the Company's Argentine subsidiaries use the Argentine Peso as their functional currency. IAS 29 requires that the financial statements of an entity whose functional currency is the currency of a hyperinflationary economy be adjusted based on an appropriate general price index to express the effects of inflation. After applying for the effects of translation, the statement of income is converted using the closing foreign exchange rate of the month. The Company restated the revenues and operating expenses of each of the following months in the three and nine-month periods ended September 30 using the following general price indexes:

	January	February	March	April	May	June	July	August	September
2024	1.67	1.48	1.33	1.22	1.17	1.12	1.08	1.04	1.00
2023	1.92	1.80	1.67	1.54	1.43	1.35	1.27	1.13	1.00

Foreign exchange

The Company records its transactions and balances in the respective functional currencies of its subsidiaries. Generally, for the LATAM subsidiaries, the functional currency is the local currency in the country where the entity operates. In order to convert a foreign-denominated transaction to the functional currency, the exchange rate prevailing at the date of the transaction is used. Furthermore, upon consolidation, for all subsidiaries with a functional currency other than CAD, the respective statements of income are translated using the average exchange rates for the period.

Exchange rate fluctuations of LATAM currencies impact the Company's results in two ways:

i. Transactional impact: certain product purchases and operating expenses are denominated in foreign currencies (mainly USD, EURO and CHF); and,
ii. Translational impact: translation of local LATAM functional currency operating results to reporting currency in CAD.

For further details on the foreign currency rates used for the conversion of selected LATAM currencies to the CAD refer to Section 7- Selected Quarterly Information.

(In thousands of Canadian dollars, except for share and per share amounts)

3.1 Consolidated Statements of Income (Loss)

			Change				Change	
	Q3-24	Q3-23	**$**	**%**	**YTD-24**	YTD-23	**$**	**%**
Revenues	**92,263**	81,500	10,763	13%	**274,440**	254,002	20,438	8%
Cost of goods sold	**47,246**	41,318	(5,928)	14%	**140,387**	135,565	(4,822)	4%
Gross margin	**45,017**	40,182	4,835	12%	**134,053**	118,437	15,616	13%
Gross margin (%)	***49%***	*49%*			***49%***	*47%*		
Expenses								
Selling and marketing	**13,372**	11,924	(1,448)	12%	**39,285**	35,463	(3,822)	11%
General and administrative	**12,110**	11,080	(1,030)	9%	**34,747**	29,305	(5,442)	19%
Research and development	**5,153**	4,768	(385)	8%	**15,939**	13,291	(2,648)	20%
Amortization of intangible assets	**11,179**	11,480	301	3%	**33,725**	33,925	200	1%
Operating income	**3,203**	930	2,273	244%	**10,357**	6,453	3,904	60%
Interest income on financial instruments measured at amortized cost	**(2,458)**	(2,024)	434	21%	**(6,554)**	(6,218)	336	5%
Other interest income	**(65)**	(1,031)	(966)	94%	**(1,194)**	(3,276)	(2,082)	64%
Interest expense	**1,915**	2,603	688	26%	**6,776**	8,398	1,622	19%
Other income	**(795)**	(1,907)	(1,112)	58%	**(1,006)**	(2,123)	(1,117)	53%
Net loss (gain) on financial assets measured at fair value through profit or loss	**2,820**	(5,562)	(8,382)	151%	**19,752**	2,346	(17,406)	742%
Foreign exchange loss	**2,326**	1,317	(1,009)	77%	**5,934**	6,162	228	4%
Gain on hyperinflation	**(1,148)**	(1,364)	(216)	16%	**(7,528)**	(3,000)	4,528	151%
Income (loss) before income taxes	**608**	8,898	(8,290)	93%	**(5,823)**	4,164	(9,987)	240%
Income tax								
Current	**1,862**	1,112	(750)	67%	**4,776**	3,251	(1,525)	47%
Deferred	**(1,339)**	(1,802)	(463)	26%	**(4,196)**	(6,578)	(2,382)	36%
Income tax expense (recovery)	**523**	(690)	(1,213)	176%	**580**	(3,327)	(3,907)	117%
Net income (loss) for the period	**85**	9,588	(9,503)	99%	**(6,403)**	7,491	(13,894)	185%
Basic and diluted net income (loss) per share	**—**	0.09	(0.09)	100%	**(0.06)**	0.07	(0.13)	186 %

(In thousands of Canadian dollars, except for share and per share amounts)

3.2 Select financial results excluding the impact of hyperinflation under IAS 29[1]

			Change				Change	
	Q3-24	Q3-23	**$**	**%**	**YTD-24**	YTD-23	**$**	**%**
Revenues	**91,430**	81,669	9,761	12%	**271,346**	254,736	16,610	7%
Cost of goods sold	**48,234**	39,548	8,686	22%	**142,173**	130,985	11,188	9%
Gross margin	**43,196**	42,121	1,075	3%	**129,173**	123,751	5,422	4%
Gross margin (%)	***47%***	*52%*			***48%***	*49%*		
Expenses								
Selling and marketing	**13,197**	11,937	1,260	11%	**38,658**	35,635	3,023	8%
General and administrative	**11,922**	11,009	913	8%	**33,711**	29,084	4,627	16%
Research and development	**5,372**	4,651	721	16%	**15,789**	13,376	2,413	18%
Amortization of intangible assets	**11,161**	11,475	(314)	3%	**33,707**	33,789	(82)	—%
Operating income	**1,544**	3,049	(1,505)	49%	**7,308**	11,867	(4,559)	38%
EBITDA[1]	**13,330**	15,512	(2,182)	14%	**42,560**	48,018	(5,458)	11%
Adjusted EBITDA[1]	**13,454**	15,512	(2,058)	13%	**42,787**	48,018	(5,231)	11%
Adjusted EBITDA per share[1]	**0.13**	0.15	(0.02)	10%	**0.42**	0.46	(0.04)	7%

[1] *Revenues and financial results excluding the impact of IAS 29, EBITDA, Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP measures. Refer to section - 15 Non-GAAP measures for additional details.*

(In thousands of Canadian dollars, except for share and per share amounts)

Revenues[1]

			Change				Change	
Therapeutic Area	**Q3-24**	**Q3-23**	**$**	**%**	**YTD-24**	**YTD-23**	**$**	**%**
Oncology/Hematology	**36,821**	31,336	5,485	18%	**103,288**	88,363	14,925	17%
Infectious Diseases	**33,827**	29,195	4,632	16%	**109,713**	105,739	3,974	4%
Other Specialty	**20,782**	21,138	(356)	2%	**58,345**	60,634	(2,289)	4%
Total	**91,430**	81,669	9,761	12%	**271,346**	254,736	16,610	7%

[1] *Excluding the impact of hyperinflation under IAS 29.*

For the quarter ended September 30, 2024, revenues increased by $9,761 or 12% compared to the same period in prior year. For the nine-month period ended September 30, 2024, revenues increased by $16,610 or 7% compared to the same period in the prior year. On a constant currency[1] basis, revenues increased by $13,801 or 18% and by $17,058 or 7% for the three and nine-month periods ended September 30, 2024.

The increase in revenues excluding the impact of hyperinflation is explained by the following:

Oncology/Hematology

Q3-24 vs Q3-23

- The oncology/hematology portfolio increased by $5,485 or 18% or $6,729 or 22% on a constant currency[1] basis driven by continued growth of key promoted products including Lenvima®, Akynzeo®, Trelstar® and the launch of Minjuvi® in Brazil.
- Furthermore, in Q3-24, a competitor in Brazil launched both a branded generic and a generic of Lenvima®. Knight and Eisai are collaborating to defend Lenvima's® market exclusivity in Brazil. While we continue to challenge the generic entrants, the introduction of generics and branded generics will increase competitive pressures and negatively impact future sales and margins of Lenvima® in Brazil.

YTD-24 vs YTD-23

- The oncology/hematology portfolio increased by $14,925 or 17%. Our promoted and newly launched products, Lenvima®, Akynzeo®, Trelstar® and Minjuvi®, grew by $17,924 or 20%. This growth was partially offset by a decline in revenues of approximately $3,000 in our mature and branded generics products due to their lifecycle and the market entrance of new competitors.

Infectious Diseases

Q3-24 vs Q3-23

- The infectious diseases portfolio increased by $4,632 or 16% or $6,572 or 24% on constant currency[1] basis mainly driven by the timing of orders for Ambisome® under the MOH contract and growth of our key promoted products including Cresemba®, partly offset by a decrease in the demand of Impavido®. During Q3-24 the Company delivered $6,700 of Ambisome® to MOH compared to nil in Q3-23.

YTD-24 vs YTD-23

- The infectious diseases portfolio increased by $3,974 or 4% due to timing of orders for Ambisome® under the MOH contract and growth of our key promoted products including Cresemba®, partly offset by a decrease in the demand of Impavido®. In YTD-24 the Company delivered $24,800 of Ambisome® to MOH compared to $20,400 in YTD-23.

MOH Contract

The Company signed a contract with the Ministry of Health of Brazil for Ambisome® in December 2022 ("2022 MOH Contract"). Knight delivered a total of $34,600 under the 2022 MOH Contract as follows: $7,000 in 2022, $25,200 in 2023 ($2,400 in Q1-23, $18,000 in Q2-23 and $4,800 in Q4-23) and $2,400 Q1-24. In December 2023, Knight signed a new contract with the MOH ("2024 MOH Contract") and has delivered $24,800 under this contract in 2024 as follows: $6,800 in Q1-24, $8,900 in Q2-24 and $6,700 in Q3-24. The total MOH sales Ambisome® delivered in Q3-24 and YTD-24 was $6,700 and $24,800, respectively.

[1] *Revenues at constant currency is a non-GAAP measure. Refer to Section 8 - Financial Results at constant currency and Section 15 - Non-GAAP measures for additional details.*

Other Specialty

Q3-24 vs Q3-23

- The other specialty portfolio decreased by $356 or 2%. There was no significant variance.

YTD-24 vs YTD-23

- The other specialty portfolio decreased by $2,289 or 4%, primarily driven by timing of sales of certain products and a decline in revenues from our mature branded generics products due to their lifecycle. This decline is partially offset by the launch of Imvexxy® and Bijuva® in Canada.

(In thousands of Canadian dollars, except for share and per share amounts)

All the pharmaceutical products sold by Knight are categorized as either innovative or BGx products. The description of each portfolio are as follows:

Innovative Portfolio: The portfolio consists of the pharmaceutical products with innovative molecules and includes both in-licensed products such as Lenvima®, Cresemba®, Halaven®, Trelstar®, Akynzeo®, Ambisome®, Minjuvi®, Imvexxy® as well as products owned (or partially owned) by Knight such as Exelon® and Impavido®. The categories of the portfolio are as follows:

- Innovative – Promoted portfolio: Consists of products on which the Company invest in commercial activities such as sales force promotion and medical activities.
- Innovative – Mature: Consists of products that require lower level of promotional activities and/or products that have reached their peak market capture potential.
- Innovative – Discontinued: Consists of products that the Company has stopped commercializing or is in the process of discontinuing sales.

BGx Portfolio: The portfolio consists of branded generic products which are pharmaceutically equivalent to an innovative molecule. The branded generics are given a brand name to differentiate the product from ordinary generics or other branded generics. The Company's branded generic portfolio currently primarily consists of products manufactured at our facilities in Argentina for commercialization in Argentina and the rest of Latin America (excluding Brazil and Mexico). The categories of portfolio are as follows:

- BGx – New Launches: Consists of branded generic pharmaceutical products in the first three years of launch.
- BGx – Mature: Consists of products which have been launched for more than three years.
- BGx – Discontinued: Consists of products that the Company has stopped commercializing or is in the process of discontinuing sales.

For the quarter ended September 30, 2024, excluding the impact of IAS 29, the Company generated $78,082 or 85% of total revenues from its innovative portfolio and $13,348 or 15% of total revenues from its BGx portfolio.

For the nine-month period ended September 30, 2024, excluding the impact of IAS 29, the Company generated $234,117 or 86% of total revenues from its innovative portfolio and $37,229 or 14% of total revenues from its BGx portfolio.

Product Portfolio			**Change**				**Change**	
Innovative	**Q3-24**	Q3-23	$	%	**YTD-24**	YTD-23	$	%
Promoted	**67,477**	53,951	13,526	25%	**202,384**	174,569	27,815	16%
Mature	**10,605**	14,759	(4,154)	28%	**31,634**	39,729	(8,095)	20%
Total excluding discontinued	**78,082**	68,710	9,372	14%	**234,018**	214,298	19,720	9%
Discontinued	**—**	9	(9)	100%	**99**	532	(433)	81%
Total	**78,082**	68,719	9,363	14%	**234,117**	214,830	19,287	9%
BGx								
New Launches	**1,576**	1,084	492	45%	**4,199**	3,532	667	19%
Mature	**11,611**	11,563	48	—%	**32,562**	35,202	(2,640)	7%
Total excluding discontinued	**13,187**	12,648	539	4%	**36,761**	38,734	(1,973)	5%
Discontinued	**161**	302	(141)	47%	**468**	1,172	(704)	60%
Total	**13,348**	12,950	398	3%	**37,229**	39,906	(2,677)	7%
Total Revenues	**91,430**	81,669	9,761	12%	**271,346**	254,736	16,610	7%

(In thousands of Canadian dollars, except for share and per share amounts)

	Change		Q3-24 vs Q3-23
Product Portfolio	**$**	**%**	
Innovative - Promoted	13,526	25%	• On a constant currency basis[1], revenues increased by $16,929 or 33%. The growth of $13,526 or 25% is driven by: • An increase of $6,900 or 37% from continued growth of key promoted products including Lenvima®, Trelstar®, Akynzeo®, Cresemba® as well as the contribution from the launches of Imvexxy® and Bijuva® in Canada and Minjuvi® in Brazil. • Incremental revenues of $6,700 related to the timing of Ambisome® orders under the MOH contract. • The purchasing patterns for certain products.
Innovative - Mature	(4,154)	28%	• A decrease in demand of Impavido®.
Innovative - Discontinued	(9)	100%	• No significant variance.
Total Innovative	**9,363**	**14%**	
BGx - New Launches	492	45%	• No significant variance.
BGx - Mature	48	—%	• No significant variance.
BGx - Discontinued	(141)	47%	• No significant variance.
Total BGx	**398**	**3%**	

	Change		YTD-24 vs YTD-23
Product Portfolio	**$**	**%**	
Innovative - Promoted	27,815	16%	• On a constant currency basis[1], revenues increased by $29,412 or 17%. The growth of $27,815 or 16% is driven by: • An increase of approximately $24,000 or 48% due to the continued growth of key promoted products including Lenvima®, Trelstar®, Akynzeo®, Cresemba® as well as the contribution from the launches of Imvexxy® and Bijuva® in Canada and Minjuvi® in Brazil. • Incremental revenues of $4,400 related to the timing of Ambisome® orders under the MOH contract. • The purchasing patterns for certain products.
Innovative - Mature	(8,095)	20%	• A decrease in demand of Impavido®.
Innovative - Discontinued	(433)	81%	• No significant variance.
Total Innovative	**19,287**	**9%**	
BGx - New Launches	667	19%	• No significant variance.
BGx - Mature	(2,640)	7%	• The lifecycle of products including entrance of new competitors.
BGx - Discontinued	(704)	60%	• No significant variance.
Total BGx	**(2,677)**	**7%**	

[1]*Revenues at constant currency is a non-GAAP measure. Refer to Section 8 - Financial Results at constant currency and Section 15 - Non-GAAP measures for additional details.*

(In thousands of Canadian dollars, except for share and per share amounts)

Gross margin[1]	**Q3-24 vs Q3-23** • Gross margin as a percentage of revenues was 47% in Q3-24 compared to 52% in Q3-23. The decrease in the gross margin, as a percentage of revenues, was due to product mix including a higher proportion of Ambisome® sales to MOH. **YTD-24 vs YTD-23** • Gross margin as a percentage of revenues was 48% in YTD-24 compared to 49% in YTD-23. There was no significant variance.
Selling and marketing[1]	**Q3-24 vs Q3-23** • For the quarter ended September 30, 2024, selling and marketing increased by $1,260 or 11%. The increase was mainly driven by the marketing spend for the launches of Minjuvi® in Brazil, Imvexxy® and Bijuva® in Canada as well as pre-launch activities for Jornay PM™. **YTD-24 vs YTD-23** • For the nine-month period ended September 30, selling and marketing increased by $3,023 or 8%. The increase was mainly driven by the marketing spend for the launches of Minjuvi® in Brazil, Imvexxy® and Bijuva® in Canada as well as pre-launch activities for Jornay PM™.
General and administrative[1]	**Q3-24 vs Q3-23** • For the quarter ended September 30, 2024, general and administrative increased by $913 or 8%. The increase was mainly driven by structure and compensation expenses along with higher spending on professional and consulting fees. **YTD-24 vs YTD-23** • For the nine-month period ended September 30, 2024, general and administrative increased by $4,627 or 16%. The increase was mainly driven by structure and compensation expenses along with higher spending on professional and consulting fees.
Research and development expenses[1]	**Q3-24 vs Q3-23** • For the quarter ended September 30, 2024, research and development expenses increased by $721 or 16%. The increase was driven by medical initiatives related to key promoted products. **YTD-24 vs YTD-23** • For the nine-month period ended September 30, 2024, research and development increased by $2,413 or 18%. The increase was driven by product development activities in connection with our pipeline products and medical initiatives related to key promoted products. Knight invested $1,519 in Q3-24, an increase of $970 versus the prior year on its pipeline development activities. All costs related to development activities have been expensed which typically include regulatory submissions, analytical method transfers, stability studies and bioequivalence studies.
Adjusted EBITDA[2]	**Q3-24 vs Q3-23** • For the quarter ended September 30, 2024, adjusted EBITDA decreased by $2,058 or 13%. The decrease was driven by higher marketing spend related to the launches of Minjuvi® in Brazil, Imvexxy® and Bijuva® in Canada as well as pre-launch activities for Jornay PM™, higher general and administrative expenses mainly related to structure and compensation increase along with higher spending on professional and consulting fees, and an increase in research and development expenses mainly driven by medical initiatives related to key promoted products, partly offset by higher revenues and corresponding gross margin.

[1] Excluding the impact of hyperinflation under IAS 29. For figures under IFRS refer to Section 3.1 - Interim Consolidated Statements of Income (loss).
[2] Adjusted EBITDA is a non-GAAP measure. Refer to Section 15 - Non-GAAP measures for additional details.

(In thousands of Canadian dollars, except for share and per share amounts)

Adjusted EBITDA[2]	**YTD-24 vs YTD-23** • For the nine-month period ended September 30, 2024, adjusted EBITDA decreased by $5,231 or 11%. The decrease was driven by higher marketing spend for the launches of Minjuvi® in Brazil, Imvexxy® and Bijuva® in Canada as well as pre-launch activities for Jornay PM™, higher general and administrative expenses mainly related to structure and compensation expenses along with higher spending on professional and consulting fees and an increase in research and development expenses driven by product development activities in connection with our pipeline products and medical initiatives related to key promoted products, partly offset by higher revenues and corresponding gross margin.
Amortization of intangible assets[1]	**Q3-24 vs Q3-23** • For the quarter ended September 30, 2024, amortization of intangible assets decreased by $314 or 3%. There was no significant variance. **YTD-24 vs YTD-23** • For the nine-month period ended September 30, 2024, amortization of intangible assets decreased by $82. There was no significant variance.
Interest income[3]	**Q3-24 vs Q3-23** • For the quarter ended September 30, 2024, interest income decreased by $532 or 17%, mainly driven by a decrease in the outstanding balance of strategic loans due to the repayment of the M8 loan in December 2023. **YTD-24 vs YTD-23** • For the nine-month period ended September 30, 2024, interest income decreased by $1,746 or 18%, mainly driven by a decrease in the outstanding balance of strategic loans due to the repayment of the M8 loan in December 2023.
Interest expense	**Q3-24 vs Q3-23** • The interest expense includes the interest expense on bank loans of $1,603 (Q3-23: $2,410) and interest expense on lease liabilities of $312 (Q3-23: $193). • For the quarter ended September 30, 2024, interest expense decreased by $688 or 26%. The decrease was due to a lower average loan balance driven by principal repayments. **YTD-24 vs YTD-23** • The interest expense includes the interest expense on bank loans of $6,069 (YTD-23: $7,759) and interest expense on lease liabilities of $707 (YTD-23: $639). • For the nine-month period ended September 30, 2024, interest expense decreased by $1,622 or 19%. The decrease was due to a lower average loan balance driven by principal repayments.
Other income	**Q3-24 vs Q3-23** • For the quarter ended September 30, 2024, other income decreased by $1,112 or 58%, mainly due to a gain on the disposal of a property in Colombia in Q3-23. **YTD-24 vs YTD-23** • For the nine-month period ended September 30, 2024, other income decreased by $1,117 or 53%, mainly due to a gain on the disposal of a property in Colombia in Q3-23.

[1] *Excluding the impact of hyperinflation under IAS 29. For figures under IFRS refer to Section 3.1 - Interim Consolidated Statements of Income (loss).*
[2] *Adjusted EBITDA is a non-GAAP measure. Refer to Section 15 - Non-GAAP measures for additional details.*
[3] *Includes Interest income on financial instruments measured at amortized cost and other interest income primarily from interest earned on loans.*

(In thousands of Canadian dollars, except for share and per share amounts)

Net gain or loss on financial assets measured at fair value through profit or loss	**Q3-24 vs Q3-23** • Net loss on financial assets measured at fair value through profit and loss was $2,820 in Q3-24, mainly driven by unrealized losses on our strategic fund investments. • Net gain on financial assets measured at fair value through profit and loss was $5,562 in Q3-23 mainly driven by: ◦ Equity investments, derivatives and loans and other receivables: Gain of $12,894 mainly due to the increase in the fair value of Moksha8 warrants and the 60P Conversion Agreement executed in Q3-23 offset by, ◦ Strategic fund investments: Loss of $7,332 mainly driven by negative mark-to-market adjustments due to the decline in share prices of publicly-traded equities. **YTD-24 vs YTD-23** • Net loss on financial assets measured at fair value through profit and loss was $19,752 in YTD-24, mainly driven by unrealized losses on the valuation of certain private investments of our strategic fund investments. • Net loss on financial assets measured at fair value through profit and loss was $2,346 in YTD-23, mainly driven by: ◦ Strategic fund investments: Loss of $15,361 mainly driven by negative mark-to-market adjustments due to the decline in share prices of publicly-trade equities offset by, ◦ Equity investments, derivatives and loans and other receivables: Gain of $13,015 mainly due to the increase in the fair value of Moksha8 warrants and the 60P conversion agreement executed in Q3-23.
Net gain or loss on financial assets measured at fair value through OCI	**Q3-24 vs Q3-23** • Net gain on financial assets measured at fair value through OCI was $14,530 in Q3-24, mainly due to the increase in the fair value due to Synergy's IPO. Refer to Section 10 - *Strategic lending and investments* for further information. • Net loss on financial assets measured at fair value through OCI was $34 in Q3-23. **YTD-24 vs YTD-23** • Net gain on financial assets measured at fair value through OCI was $14,598 in YTD-24, mainly due to the increase in the fair value due to Synergy's IPO. Refer to Section 10 - *Strategic lending and investments* for further information. • Net loss on financial assets measured at fair value through OCI was $51 in YTD-23.
Foreign exchange loss	**Q3-24 vs Q3-23** • The foreign exchange loss was $2,326 in Q3-24 , mainly driven by the appreciation of CAD vs USD. • The foreign exchange loss was $1,317 in Q3-23, mainly driven by the appreciation of select LATAM currencies vs the CAD. **YTD-24 vs YTD-23** • The foreign exchange loss was $5,934 in YTD-24, mainly driven by losses on intercompany balances due to the depreciation of the BRL and COP vs USD. • The foreign exchange loss was $6,162 in YTD-23, mainly driven by the appreciation of select LATAM currencies vs the CAD.

(In thousands of Canadian dollars, except for share and per share amounts)

Gain on hyperinflation	• Relates to gain on net monetary position (monetary assets less monetary liabilities) under hyperinflation accounting. Refer to Hyperinflation section above for further details. • Refer to Note 2.3 - *Summary of significant accounting policies* in the Annual Financial Statements for further details on hyperinflation accounting.
Income tax expense (recovery)	**Q3-24 vs Q3-23** • The income tax expense was $523 in Q3-24, driven by the current tax expense due to our operating income in certain jurisdictions and timing differences related to certain intercompany transactions partly offset by deferred income tax recovery due to timing difference of certain intangible assets and operating losses in certain jurisdictions. • The income tax recovery was $690 in Q3-23, driven by the recognition of certain deferred income tax assets due to tax losses generated in certain jurisdictions and timing differences related to our financial assets. **YTD-24 vs YTD-23** • The income tax expense was $580 in YTD-24, driven by the current income tax expense due to our operating income in certain jurisdictions and timing differences related to certain intercompany transactions partly offset by the recognition of deferred tax assets in connection with tax losses generated in certain jurisdictions and timing differences related to our financial assets and intangible assets. • The income tax recovery was $3,327 in YTD-23, driven by the recognition of certain deferred income tax assets due to tax losses generated in certain jurisdictions and timing differences related to our financial assets.

(In thousands of Canadian dollars, except for share and per share amounts)

FINANCIAL CONDITION

Section 4 – Consolidated Balance Sheets

4.1 Hyperinflation

Under IAS 29, all non-monetary assets and liabilities are restated in ARS by applying the inflation index from the beginning of the reporting period to the end of the reporting period. Those assets and liabilities are then translated from ARS to CAD by applying the exchange rate at the end of the reporting period. The inflation index from January 1, 2024 to September 30, 2024 was 102%, while the ARS to CAD depreciated by 17%. Consequently, non-monetary assets and liabilities held in Argentina increased in value when converted to CAD under IFRS ("YTD-24 Hyperinflation Impact").

4.2 Impact of foreign exchange volatility

Assets and liabilities on the balance sheet are converted from foreign currency to CAD using the quarter-end closing rates at the end of each reporting period. For further details on the foreign currency rates used for the conversion of selected LATAM currencies to the CAD refer to Section 7- Selected Quarterly Information.

4.3 Balance Sheet

			Change	
As at	**September 30, 2024**	December 31, 2023	**$**	**%**
ASSETS				
Current				
Cash and cash equivalents	**73,755**	58,761	14,994	26%
Marketable securities	**73,965**	95,657	(21,692)	23%
Trade receivables	**91,250**	88,722	2,528	3%
Other receivables	**7,294**	7,427	(133)	2%
Inventories	**114,959**	91,834	23,125	25%
Prepaids and deposits	**7,287**	4,881	2,406	49%
Other current financial assets	**24,598**	15,753	8,845	56%
Income taxes receivable	**4,458**	2,080	2,378	114%
Total current assets	**397,566**	365,115	32,451	9%
Marketable securities	**3,780**	7,407	(3,627)	49%
Prepaids and deposits	**7,682**	7,767	(85)	1%
Right-of-use assets	**6,352**	6,190	162	3%
Property, plant and equipment	**15,292**	11,669	3,623	31%
Intangible assets	**279,681**	289,960	(10,279)	4%
Goodwill	**84,783**	79,844	4,939	6%
Other financial assets	**101,859**	112,616	(10,757)	10%
Deferred income tax assets	**20,900**	19,390	1,510	8%
Other long-term receivables	**44,399**	45,535	(1,136)	2%
Total non-current assets	**564,728**	580,378	(15,650)	3%
Total assets	**962,294**	945,493	16,801	2%

(In thousands of Canadian dollars, except for share and per share amounts)

			Change	
As at	**September 30, 2024**	December 31, 2023	**$**	**%**
LIABILITIES AND EQUITY				
Current				
Accounts payable and accrued liabilities	**86,620**	85,366	1,254	1%
Lease liabilities	**3,015**	1,728	1,287	74%
Other liabilities	**2,193**	1,046	1,147	110%
Bank loans	**18,691**	17,850	841	5%
Income taxes payable	**2,493**	1,182	1,311	111%
Other balances payable	**5,140**	6,857	(1,717)	25%
Total current liabilities	**118,152**	114,029	4,123	4%
Accounts payable and accrued liabilities	**7,175**	5,251	1,924	37%
Lease liabilities	**3,551**	5,497	(1,946)	35%
Bank loans	**32,960**	44,016	(11,056)	25%
Other balances payable	**22,284**	27,012	(4,728)	18%
Deferred income tax liabilities	**4,263**	2,817	1,446	51%
Total liabilities	**188,385**	198,622	(10,237)	5%
Shareholders' Equity				
Share capital	**539,317**	540,046	(729)	—%
Warrants	**117**	117	—	—%
Contributed surplus	**26,215**	25,991	224	1%
Accumulated other comprehensive income	**64,077**	29,829	34,248	115%
Retained earnings	**144,183**	150,888	(6,705)	4%
Total shareholders' equity	**773,909**	746,871	27,038	4%
Total liabilities and shareholders' equity	**962,294**	945,493	16,801	2%

(In thousands of Canadian dollars, except for share and per share amounts)

	Q3-24 vs Q4-23
Cash and cash equivalents and marketable securities	• Refer to Section 5 - Liquidity and Capital Resources for further information.
Trade receivables	• Trade receivables were $91,250, an increase of $2,528 or 3%, mainly due to the growth in revenues in Q3-24 compared to Q4-23.
Other receivables (current)	• Other receivables were $7,294, a decrease of $133 or 2%. There was no significant variance.
Inventories	• Inventories were $114,959, an increase of $23,125 or 25%. Excluding the YTD-24 Hyperinflation Impact, inventories increased by $11,104 or 12% due to timing of purchases as well as investments on our new product launches.
Prepaids and deposits (current and long term)	• Prepaids and deposits were $14,969, an increase of $2,321 or 18% mainly due to advance payments to certain suppliers.
Other financial assets (current and long term)	• Other financial assets were $126,457, a decrease of $1,912 or 1%, mainly explained by the following: **Funds**: decreased by $19,024 or 17% driven mainly by unrealized losses on the valuation of certain private investments of our strategic funds. Refer to Section 10 - *Strategic lending and investments* for further information. **Equity investments and Derivatives**: increased by $13,118 or 353% mainly due to the increase in the fair value due to Synergy's IPO. Refer to Section 10 - *Strategic lending and investments* for further information. **Loans and other receivables**: increased by $3,994 or 25% mainly driven by trade & other receivables capitalization into loan outstanding balance by $3,053, interest and foreign exchange gain.
Income taxes receivable	• Income taxes receivable were $4,458, an increase of $2,378 or 114%, mainly due timing of tax installments.
Right-of-use assets	• Right-of-use assets were $6,352, an increase of $162 or 3%. There was no significant variance.
Property, plant and equipment	• Property, plant and equipment was $15,292, an increase of $3,623 or 31%, mainly due to the YTD-24 Hyperinflation Impact.
Intangible assets	• Intangible assets were $279,681, a decrease of $10,279 or 4%, mainly due to amortization, partially offset by upfront and milestone payments in connection with certain product licensing agreements including IPX203 and Jornay PM™ and the appreciation of USD vs CAD.
Goodwill	• Goodwill was $84,783, an increase of $4,939 or 6%, mainly due to the YTD-24 Hyperinflation Impact.
Deferred income tax assets	• Deferred income tax assets were $20,900, an increase of $1,510 or 8%, mainly due to the recognition of tax losses in certain jurisdictions and timing differences related to our financial assets and intangible assets.
Other receivables (long-term)	• Other receivables were $44,399, a decrease of $1,136 or 2%. There was no significant variance.

(In thousands of Canadian dollars, except for share and per share amounts)

	Q3-24 vs Q4-23
Accounts payable and accrued liabilities (current and long term)	• Accounts payable and accrued liabilities were $93,795. As at December 31, 2023, the accounts payable and accrued liabilities included $6,922 of payables related to sales milestones on certain products and the acquisition of property, plant and equipment ("Capital Expenditure Payables"). Excluding the Capital Expenditure Payables the accounts payable and accrued liabilities increased by $10,100 or 11% compared to December 31, 2023, mainly driven by timing of purchases of inventory as well as investments on our new product launches.
Lease liabilities (current and long term)	• Lease liabilities were $6,566, a decrease of $659 or 9%. There was no significant variance.
Other liabilities	• Other liabilities were $2,193, an increase of $1,147 or 110%. The increase is due to certain accounting provisions.
Bank loans (current and long term)	• Bank loans were $51,651, a decrease of $10,215 or 17%, mainly due to principal repayments of bank loans as well as the depreciation of the BRL, MXN and the COP.
Income taxes payable	• Income taxes payable were $2,493, an increase of $1,311 or 111% mainly explained by operating income in certain jurisdictions.
Other balances payable (current and long term)	• Other balances payable was $27,424, a decrease of $6,445 or 19%, mainly due to payments of milestones in accordance with license agreements.
Deferred income tax liabilities	• Deferred income tax liabilities were $4,263, an increase of $1,446 or 51%, mainly due to the YTD-24 Hyperinflation Impact.
Share capital	• Share capital was $539,317, a decrease of $729 or nil %, mainly due to the purchase of common shares through the NCIB, partially offset by the issuance of common shares under the stock-based compensation plans and ESPP. • Refer to the statement of changes in equity in the Interim Financial Statements for further information.
Contributed surplus	• Contributed surplus was $26,215, an increase of $224 or 1%. Refer to the statement of changes in equity in the Interim Financial Statements for further information.
Accumulated other comprehensive loss	• Accumulated other comprehensive loss was $64,077, an increase of $34,248 or 115%. Refer to the consolidated statement of changes in equity in the Interim Financial Statements for further information.
Retained earnings	• Retained earnings were $144,183, a decrease of $6,705 or 4%. Refer to the consolidated statement of changes in equity in the Interim Financial Statements for further information.

Notices of Reassessment

Knight received notices of reassessment from the CRA and the QRA in July 2018 and January 2019, respectively. The notices relate to the 2014 disposition of a PRV held by Knight's wholly-owned subsidiary, Knight Therapeutics International S.A. A PRV is a transferable asset that entitles the holder to a priority review for a drug of its choice.

The Company's PRV was granted on March 19, 2014, upon the FDA approval of Impavido® and was disposed of to a third party in November 2014 for gross proceeds of US$125,000. The notices of reassessment provide that Knight is liable to pay an aggregate of $23,340 and $18,242 to the CRA and QRA, respectively, in additional taxes and interest. Knight has made a deposit for the full amount to the CRA in July 2018 and to the QRA in February 2019. In addition, interest income on the deposit is payable to Knight by the CRA and QRA if the Company wins the process. The amount, as at September 30, 2024 is estimated at $6,768 and has not been recorded by the Company.

Knight believes the reassessments are unfounded and filed a notice of objection with the CRA in September 2018 to start the appeals process. In October 2021, the CRA responded to Knight's notice of objection with a confirmation of their initial tax reassessments. Knight filed a notice of appeal to the Tax Court of Canada in December 2021. The appeal hearing is scheduled for April 2025.

(In thousands of Canadian dollars, except for share and per share amounts)

Based on the Company's view of the likely outcome of the appeals process, Knight expects to recover the total of $41,582 deposited with the taxation authorities and has not recorded any tax provision related to the disposal of the PRV in its financial statements. However, there can be no assurance regarding the outcome or when a resolution may be reached.

Although Knight believes its tax provisions are adequate, the final determination of tax audits and any related disputes could be materially different from historical income tax provisions and accrual.

Section 5 – Liquidity, Capital Resources and Cash flows

The Company's Investment Policy governs the investment activities relating to cash resources. An Investment Committee composed of representatives from management and the Board of Directors monitors compliance with said policy. The Company invests in strategic investments in the form of equity funds, debt funds, equity or liquid investment securities with varying terms to maturity, selected with regard to the expected timing of investments and expenditures for continuing operations and prevailing interest rates.

The Company believes that its existing cash, cash equivalents and marketable securities as well as cash generated from operations are sufficient to finance its current operations, working capital requirements and future product and corporate acquisitions.

The table below sets forth a summary of cash flow activity and should be read in conjunction with our consolidated statements of cash flows.

			Change				Change	
	Q3-24	Q3-23	**$**	**%**	**YTD-24**	YTD-23	**$**	**%**
Net cash inflow from operating activities	**5,016**	15,166	(10,150)	67%	**34,811**	17,996	16,815	93%
Net cash inflow (outflow) from investing activities	**11,527**	35,756	(24,229)	68%	**(1,086)**	31,242	(32,328)	103%
Net cash outflow from financing activities	**(3,927)**	(11,239)	7,312	65%	**(18,186)**	(45,304)	27,118	60%
Increase in cash and cash equivalents, during the period	**12,616**	39,683	(27,067)	68%	**15,539**	3,934	11,605	295%
Net foreign exchange difference	**332**	(109)	441	405%	**(545)**	1,805	(2,350)	130%
Cash and cash equivalents, beginning of the period	**60,807**	37,844	22,963	61%	**58,761**	71,679	(12,918)	18%
Cash and cash equivalents, end of the period	**73,755**	77,418	(3,663)	5%	**73,755**	77,418	(3,663)	5%
Marketable securities, end of the period	**77,745**	76,397	1,348	2%	**77,745**	76,397	1,348	2%
Cash and cash equivalents, and marketable securities, end of the period	**151,500**	153,815	(2,315)	2%	**151,500**	153,815	(2,315)	2%
Cash and cash equivalents, net of bank loans	**22,104**	78,451	(56,347)	72%	**22,104**	78,451	(56,347)	72%

	Q3-24 / **YTD-24**
Net cash from operating activities	Primarily relates to cash generated through revenues and interest received, offset by operating expenses including salaries, research and development expenses, advertising and promotion costs and other corporate expenses. Cash flows from operating activities exclude revenues and expenses not affecting cash, such as unrealized and realized gains or losses on financial assets, share based compensation expense, depreciation and amortization, unrealized foreign exchange gains or losses, hyperinflation gains, other income, deferred other income, and net changes in non-cash balances relating to operations.

	For the three-month period ended September 30, 2024, cash inflow from operations was $5,016, driven by the operating results adjusted for non-cash items such as depreciation, amortization and an increase in working capital of $10,992. The increase was mainly due to: • an increase of $10,003 in account receivables and other receivables mainly due to the timing of collections from customers • an increase of $9,641 in inventories excluding the YTD-24 Hyperinflation Impact driven by timing of purchases as well as investments on our new product launches. • an increase of $9,420 in accounts payable mainly related to inventory purchases of our key promoted products as well as investments on our new product launches. Refer to Note 10 - Statement of Cash Flows of the Interim Condensed Consolidated Financial Statements for further details on the changes in the working capital. Furthermore, the net cash from operating activities included an inflow of $1,910 related to interest received upon maturity of marketable securities.	For the nine-month period ended September 30, 2024, cash inflow from operations was $34,811, driven by the operating results adjusted for noncash items such as depreciation, amortization and an increase in working capital of $7,416. The increase in the working capital was mainly due to: • an increase of $11,104 in inventories excluding the YTD-24 Hyperinflation Impact driven by timing of purchases as well as investments on our new product launches. • an increase of $4,399 in accounts receivable and other receivables mainly due to the revenue growth in Q3-24 compared to Q4-23. • an increase of $10,100 in accounts payable and accrued liabilities after excluding Capital Expenditure Payables mainly driven by inventory purchases of our key promoted products as well as investments on our new product launches. Refer to Note 10 - Statement of Cash Flows of the Interim Condensed Consolidated Financial Statements for further details on the changes in the working capital. Furthermore, the net cash from operating activities included an inflow of $6,304 related to interest received upon maturity of marketable securities.
Net cash from investing activities	For the three-month period ended September 30, 2024, cash flows were mainly driven by: • net proceeds from marketable securities of $13,286; • acquisition of intangibles of $1,671 primarily for milestone payments in connection with certain license agreements.	For the nine-month period ended September 30, 2024, cash flows were mainly driven by: • acquisition of intangibles of $28,488 primarily for upfront and milestone payments in connection with certain licensing agreements including Qelbree™, IPX203, Jornay PM™, Cresemba® and certain other products; • net proceeds from marketable securities of $27,354.
Net cash from financing activities	Cash flows from financing activities were mainly due to the repurchase of common shares through the NCIB, principal and interest repayments on bank loans, principal repayments on lease liabilities, proceeds from bank loans and proceeds from the participation of employees and directors in the Company's share purchase and stock option plans.	

(In thousands of Canadian dollars, except for share and per share amounts)

	Q3-23	YTD-23
Net cash from operating activities	Primarily relates to cash generated through revenues and interest received, offset by operating expenses including salaries, research and development expenses, advertising and promotion costs and other corporate expenses. Cash flows from operating activities exclude revenues and expenses not affecting cash, such as unrealized and realized gains or losses on financial assets, share based compensation expense, depreciation and amortization, unrealized foreign exchange gains or losses, hyperinflation gains, deferred other income, and net changes in non-cash balances relating to operations.	
	For the three-month period ended September 30, 2023, cash inflow from operations was $15,166, driven by the operating results adjusted for noncash items such as depreciation and amortization offset by an increase in working capital of $7,235. The increase in the working capital is mainly due to increase in inventory related to our key promoted products including Lenvima® and Trelstar®, the settlement of accounts payable mainly related to inventory purchases, offset by the decrease in accounts receivable as a result of collections during the period. Refer to note 16 of the interim consolidated financial statements for further details on the changes in the working capital. Furthermore, the net cash from operating activities included an inflow of $4,327 mainly related to interest received upon maturity of marketable securities and interests on our bank accounts.	For the nine-month period ended September 30, 2023, cash inflow from operations was $17,996 driven by the operating results adjusted for noncash items such as depreciation and amortization offset by an increase in working capital of $33,303. The increase in the working capital is mainly due to increase in inventory related to our key promoted products including Lenvima® and Exelon®, the settlement of accounts payable mainly related to inventory purchases of our key promoted products, offset by the decrease in accounts receivable as a result of collections during the period. Refer to note 10 of the interim consolidated financial statements for further details on the changes in the working capital. Furthermore, the net cash from operating activities included an inflow of $9,680 mainly related to interest received upon maturity of marketable securities, bank accounts yields and other short-term investments.
Net cash from investing activities	For the three-month period ended September 30, 2023, cash flows were mainly driven by: • net proceeds from marketable securities of $29,086; and • cash inflow from the principal repayment of $7,417 mainly from Moksha8.	For the nine-month period ended September 30, 2023, cash flows were mainly driven by: • net proceeds from marketable securities of $24,704; • acquisition of intangibles of $7,727 mainly due to sales and regulatory milestones on certain products including the in-licensing of Akynzeo® and Aloxi® from Helsinn; and • proceeds from disposal of investments in Medimetriks of $2,347; and • cash inflow from the principal repayment of $12,774 mainly from Moskha8.
Net cash from financing activities	Cash flows from financing activities were mainly due to the repurchase of common shares through the NCIB, principal and interest repayments on bank loans, principal repayments on lease liabilities, proceeds from bank loans and proceeds from the participation of employees and directors in the Company's share purchase plan.	

(In thousands of Canadian dollars, except for share and per share amounts)

Section 6 – Segment Reporting

The Company had one reportable segment, namely the development, acquisition, in-licensing, out-licensing, marketing and distribution of innovative pharmaceutical products, consumer health products and medical devices. This reflects the revised management structure and the way that the chief operating decision-maker evaluates the business.

Geographic Information

The following table represents the revenues excluding IAS 29 per country, based on where the customer is located.

	Three months ended September 30,				Nine months ended September 30,			
			Change				Change	
Revenue	**2024**	2023	**$**	**%**	**2024**	2023	**$**	**%**
Brazil	**41,073**	31,538	9,535	30%	**133,300**	122,879	10,421	8%
Colombia	**15,249**	12,843	2,406	19%	**41,498**	32,501	8,997	28%
Argentina	**11,108**	9,645	1,463	15%	**29,658**	28,937	721	2%
Rest of LATAM	**15,480**	16,659	(1,179)	7%	**43,562**	43,109	453	1%
Canada	**6,115**	5,108	1,007	20%	**16,696**	13,943	2,753	20%
Other[1]	**2,405**	5,876	(3,471)	59%	**6,632**	13,367	(6,735)	50%
Total	**91,430**	81,669	9,761	12%	**271,346**	254,736	16,610	7%

[1] *Includes Europe, US and other countries.*

Brazil

Q3-24 vs Q3-23

- For the quarter ended September 30, 2024, revenues increased by $9,535 or 30% or $12,844 or 45% on a constant currency[1] basis, mainly due to the timing of orders for Ambisome® under the MOH contract, the growth of our key promoted products including Lenvima® and the launch of Minjuvi®. During Q3-24 the Company delivered $6,700 of Ambisome® to MOH compared to nil in Q4-23.
- Furthermore, in Q3-24, a competitor in Brazil launched both a branded generic and a generic of Lenvima®. Knight and Eisai are collaborating to defend Lenvima's® market exclusivity in Brazil. While we continue to challenge the generic entrants, the introduction of generics and branded generics will increase competitive pressures and negatively impact future sales and margins of Lenvima in Brazil.

YTD-24 vs YTD-23

- For the nine-month period ended September 30, 2024, revenues increased by $10,421 or 8% or $13,112 or 11% on a constant currency[1] basis, mainly due to the growth of our key promoted products including Cresemba® and Lenvima® as well as the launch of Minjuvi® and the revenues from Ambisome® under the MOH contract. On a YTD basis in Q3-24 the Company delivered $24,800 to MOH compared to $20,400 in YTD-23.

Colombia

Q3-24 vs Q3-23

- For the quarter ended September 30, 2024, revenues increased by $2,406 or 19%, mainly driven by the growth of key promoted products including Lenvima® and Cresemba®, partially offset by lifecycle of our mature products.

[1] *Revenues at constant currency is a non-GAAP measure. Refer to Section 8 - Financial Results at constant currency and Section 15 - Non-GAAP measures for additional details.*

(In thousands of Canadian dollars, except for share and per share amounts)

Colombia	**YTD-24 vs YTD-23** • For the nine-month period ended September 30, 2024, revenues increased by $8,997 or 28% or or $6,230 or 18% on a constant currency[1] basis, mainly driven by the growth of key promoted products including Lenvima® and Cresemba®, partially offset by a lifecycle of our mature products.
Argentina	**Q3-24 vs Q3-23** • For the quarter ended September 30, 2024, revenues increased by $1,463 or 15%, mainly driven by growth of key promoted products including Akynzeo® and Cresemba® as well as the timing of sales of our mature products. **YTD-24 vs YTD-23** • For the nine-month period ended September 30, 2024, revenues increased by $721 or 2%, mainly driven by the growth of key promoted products including Akynzeo® and Cresemba®, partially offset by a lifecycle of our mature products.
Rest of LATAM	**Q3-24 vs Q3-23** • For the quarter ended September 30, 2024, revenues decreased by $1,179 or 7%, due to timing of orders from certain customers as well as lifecycle of our mature products, partially offset by growth in key promoted brands, including Lenvima®. **YTD-24 vs YTD-23** • For the nine-month period ended September 30, 2024, revenues, increased by $453 or 1% driven by the growth of key promoted products including Lenvima® and Cresemba®, partially offset by a lifecycle of our mature products.
Canada	**Q3-24 vs Q3-23** • For the quarter ended September 30, 2024, revenues increased by $1,007 or 20%, mainly driven by the growth of key promoted products including Akynzeo®, Trelstar®, as well as Imvexxy® and Bijuva® launched in Q1-24. **YTD-24 vs YTD-23** • For the nine-month period ended September 30, 2024, revenues increased by $2,753 or 20%, mainly driven by the growth of key promoted products including Akynzeo®, Trelstar®, as well as Imvexxy® and Bijuva® launched in Q1-24, partly offset by the lifecycle of mature products.
Other countries	**Q3-24 vs Q3-23** • For the quarter ended September 30, 2024, revenues decreased by $3,471 or 59%, due to a decrease in the demand of Impavido®. **YTD-24 vs YTD-23** • For the nine-month period ended September 30, 2024, revenues decreased by $6,735 or 50%, due to a decrease in the demand of Impavido®.

As at September 30, 2024 and December 31, 2023, non-current operating assets consisting of property, plant and equipment, intangible assets, goodwill, right-of-use assets and other long-term receivables were held in the following geographic areas:

As at	**September 30, 2024**	December 31, 2023
	$	$
Canada	**72,414**	74,401
Brazil	**49,957**	57,351
Argentina	**36,767**	26,544
Colombia	**13,820**	15,632
Uruguay	**177,208**	181,308
Luxembourg	**35,683**	38,635
Rest of LATAM	**44,658**	39,327
Total	**430,507**	433,198

Section 7 – Selected Quarterly Information

Summary Financial information

	Q3-24	Q2-24	Q1-24	Q4-23	Q3-23	Q2-23	Q1-23	Q4-22
Revenues	**92,263**	95,573	86,604	74,197	81,500	89,905	82,597	81,655
Gross margin[1] %	**47%**	48%	47%	48%	52%	45%	50%	50%
Net income (loss)	**85**	(1,942)	(4,546)	(24,326)	9,588	1,840	(3,937)	(15,188)
Adjusted EBITDA[2]	**13,454**	15,744	13,589	12,057	15,512	14,269	18,237	13,821
Adjusted EBITDA %	**15%**	17%	16%	16%	19%	16%	22%	17%
Adjusted EBITDA per share[2]	**0.13**	0.16	0.13	0.15	0.15	0.13	0.17	0.12
EPS - Basic and diluted	**—**	(0.02)	(0.04)	(0.23)	0.09	0.02	(0.04)	(0.13)
Common shares outstanding (in thousands)	**100,976**	101,327	101,187	101,170	105,045	107,177	110,082	112,206
Cash, cash equivalents and marketable securities	**151,500**	152,668	181,859	161,825	153,815	141,623	160,469	172,674
Total assets	**962,294**	945,364	968,205	945,493	1,011,149	1,013,743	1,044,774	1,054,836
Total non-current liabilities	**70,233**	76,734	89,831	84,593	81,407	84,549	90,453	87,658

[1] Gross margin excluding the impact of hyperinflation under IAS 29
[2] Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP measures. Refer to section 15 - Non-GAAP measures for additional details.

(In thousands of Canadian dollars, except for share and per share amounts)

Foreign Currency Exchange Rates

The table below summarizes the average foreign exchange rates used for the conversion of the statement of income (loss) for selected currencies:

Rates	Q3-24	Q2-24	Q1-24	Q4-23	Q3-23	Q2-23	Q1-23	Q4-22
BRL	**4.07**	3.81	3.67	3.64	3.64	3.69	3.84	3.87
ARS	**690**	647	619	304	229	172	142	119
COP	**3,006**	2,876	2,910	2,992	3,019	3,298	3,525	3,550
CLP	**682**	683	703	659	635	596	600	674
MXN	**14.47**	13.25	12.40	12.81	12.79	12.97	13.45	14.44
USD	**0.73**	0.73	0.74	0.73	0.75	0.74	0.74	0.74

The below table summarizes the variances quarter over quarter for selected currencies:

Variance (%)	Q3-24	Q2-24	Q1-24	Q4-23	Q3-23	Q2-23	Q1-23	Q4-22
BRL	**(7%)**	(4%)	(1%)	—%	1%	4%	1%	4%
ARS	**(7%)**	(5%)	(103%)	(33%)	(33%)	(21%)	(19%)	(15%)
COP	**(5%)**	1%	3%	1%	8%	6%	1%	(6%)
CLP	**—%**	3%	(7%)	(4%)	(6%)	1%	11%	5%
MXN	**(9%)**	(7%)	3%	—%	1%	4%	7%	4%
USD	**—%**	1%	(1%)	2%	—%	(1%)	—%	4%

The following table represents Knight's quarter-end closing rates to convert the assets and liabilities on the balance sheet at the end of each reporting period.

Rates	Q3-24	Q2-24	Q1-24	Q4-23
BRL	**4.03**	4.07	3.69	3.67
ARS	**716**	666	633	610
COP	**3,093**	3,042	2,863	2,933
CLP	**666**	693	724	664
MXN	**14.56**	13.36	12.25	12.79
USD	**0.74**	0.73	0.74	0.76

The below table summarizes the variances quarter over quarter for selected currencies:

Variance (%)	Q3-24	Q2-24	Q1-24	Q4-23
BRL	**1%**	(10%)	(1%)	1%
ARS	**(8%)**	(5%)	(4%)	(137%)
COP	**(2%)**	(6%)	2%	2%
CLP	**4%**	4%	(9%)	(1%)
MXN	**(9%)**	(9%)	4%	1%
USD	**(1%)**	1%	2%	(2%)

(In thousands of Canadian dollars, except for share and per share amounts)

Section 8 - Financial Results at Constant Currency[1]

	Three months ended September 30,				Nine months ended September 30,			
	Excluding impact of IAS 29							
		Constant Currency[1]	Change			*Constant Currency[1]*	Change	
	2024	2023	$	%	**2024**	2023	**$**	**%**
Revenues	**91,430**	77,629	13,801	18%	**271,346**	254,288	17,058	7%
Cost of goods sold	**48,234**	37,093	(11,141)	30%	**142,173**	129,983	(12,190)	9%
Gross margin	**43,196**	40,536	2,660	7%	**129,173**	124,305	4,868	4%
Gross margin (%)	***47%***	*52%*			***48%***	*49%*		
Expenses								
Selling and marketing	**13,197**	11,378	(1,819)	16%	**38,658**	35,281	(3,377)	10%
General and administrative	**11,922**	10,760	(1,162)	11%	**33,711**	29,336	(4,375)	15%
Research and development	**5,372**	4,540	(832)	18%	**15,789**	13,361	(2,428)	18%
Amortization of intangible assets	**11,161**	11,604	443	4%	**33,707**	34,045	338	1%
Operating income	**1,544**	2,254	(710)	31%	**7,308**	12,282	(4,974)	40%
EBITDA[1]	**13,330**	14,757	(1,427)	10%	**42,560**	48,672	(6,112)	13%
Adjusted EBITDA[1]	**13,454**	14,757	(1,303)	9%	**42,787**	48,672	(5,885)	12%

[1] EBITDA, Adjusted EBITDA and financial results at constant currency are a non-GAAP measures. Refer to section - 15 Non-GAAP measures for additional details.

Revenues at Constant Currency[1] by Therapeutic Area

	Three months ended September 30,				Nine months ended September 30,			
	Excluding impact of IAS 29							
		Constant Currency[1]				*Constant Currency[1]*		
Innovative	**2024**	2023	$	%	**2024**	2023	$	%
Oncology/Hematology	**36,821**	30,092	6,729	22%	**103,288**	88,979	14,309	16%
Infectious Diseases	**33,827**	27,255	6,572	24%	**109,714**	104,687	5,027	5%
Other Specialty	**20,782**	20,282	500	2%	**58,344**	60,622	(2,278)	4%
Total	**91,430**	77,629	13,801	18%	**271,346**	254,288	17,058	7%

[1] Revenues at constant currency is a non-GAAP measure. Refer to Section 15 - Non-GAAP measures for additional details.

(In thousands of Canadian dollars, except for share and per share amounts)

Revenues at Constant Currency[1] by Product Portfolio

	Three months ended September 30,				Nine months ended September 30,			
			Excluding impact of IAS 29					
		Constant Currency[1]				*Constant Currency[1]*		
Innovative	**2024**	2023	$	%	**2024**	2023	$	%
Promoted	**67,477**	50,548	16,929	33%	**202,384**	172,972	29,412	17%
Mature	**10,605**	14,166	(3,561)	25%	**31,634**	39,981	(8,347)	21%
Total excluding discontinued	**78,082**	64,714	13,368	21%	**234,018**	212,953	21,065	10%
Discontinued	**—**	8	(8)	100%	**99**	629	(530)	84%
Total	**78,082**	64,722	13,360	21%	**234,117**	213,582	20,535	10%
BGx								
New Launches	**1,576**	1,093	483	44%	**4,199**	3,833	366	10%
Mature	**11,611**	11,519	92	1%	**32,562**	35,576	(3,014)	8%
Total excluding discontinued	**13,187**	12,612	575	5%	**36,761**	39,409	(2,648)	7%
Discontinued	**161**	295	(134)	45%	**468**	1,297	(829)	64%
Total	**13,348**	12,907	441	3%	**37,229**	40,706	(3,477)	9%
Total Revenues	**91,430**	77,629	13,801	18%	**271,346**	254,288	17,058	7%

[1] *Revenues at constant currency is a non-GAAP measure. Refer to Section 15 - Non-GAAP measures for additional details.*

Revenues at Constant Currency[1] by Country

The following table represents the revenues excluding IAS 29 compared to constant currency per country, based on where the customer is located.

	Three months ended September 30,				Nine months ended September 30,			
			Excluding impact of IAS 29					
		Constant Currency[1]	**Change**			*Constant Currency[1]*	**Change**	
Revenue	**2024**	2023	**$**	**%**	**2024**	2023	**$**	**%**
Brazil	**41,073**	28,229	12,844	45%	**133,300**	120,188	13,112	11%
Colombia	**15,249**	12,914	2,335	18%	**41,498**	35,268	6,230	18%
Argentina	**11,108**	9,645	1,463	15%	**29,658**	28,937	721	2%
Rest of LATAM	**15,480**	15,864	(384)	2%	**43,562**	41,828	1,734	4%
Canada	**6,115**	5,108	1,007	20%	**16,696**	13,943	2,753	20%
Other[2]	**2,405**	5,869	(3,464)	59%	**6,632**	14,124	(7,492)	53%
Total	**91,430**	77,629	13,801	18%	**271,346**	254,288	17,058	7%

[1] *Revenues at constant currency is a non-GAAP measure. Refer to Section 15 - Non-GAAP measures for additional details.*

[2] *Includes Europe, US and other countries.*

PRODUCT ACQUISITION STRATEGY

Section 9 – Products

The Company's focus is to market and sell innovative products and engage in the development, manufacturing and marketing of specialty pharmaceutical branded generic products in Latin America and Canada, as well as select international markets. Knight expects to expand its product portfolio within existing therapeutic fields in Canada and LATAM and intends to leverage its expertise in specialty sales and marketing, branded generic development, product acquisition and in-licensing to gain a competitive advantage in delivering pharmaceutical products to the marketplace, thereby decreasing scientific risks, long development timelines and high development costs. In addition, Knight's wholly owned subsidiary, Knight Therapeutics International S.A., develops innovative pharmaceuticals including those used to treat neglected tropical diseases and rare pediatric diseases.

The Company's priority is to leverage its existing infrastructure in LATAM and Canada by pursuing multiple avenues of growth that will further strengthen its platform and position Knight as a key player in the pan-American (ex-US) pharmaceutical market. The Company is pursuing a three-pronged strategy to build its product portfolio.

1. Acquisition of products, portfolios and companies

Knight is pursuing the acquisition of innovative products including portfolios that have been launched and marketed primarily by large pharmaceutical companies for a number of years. The acquisition of legacy pharmaceutical products from global companies is accretive to Knight's profitability and represents an opportunity to build a portfolio of owned assets with valuable and well-established brands. The Company is also pursuing bolt-on corporate acquisitions in certain key markets that would further optimize its platform including footprint, capabilities, and portfolio.

The following are examples of the execution of this strategy via acquisition:

Date	Product	Description
Q1-14	Impavido®	Worldwide rights to Impavido® as part of its business separation agreement with Paladin Labs Inc.
Q4-19	—	Controlling stake of 51.2% in Grupo Biotoscana
Q3-20	—	Acquired remaining public float for a 100% acquisition of Grupo Biotoscana
Q2-21	Exelon®	Exclusive rights to manufacture, market and sell Exelon® in Canada and Latin America

2. In-licensing of innovative products

The Company is pursuing the in-licensing of innovative late-stage products in its key therapeutic areas that include oncology/hematology, infectious diseases, immunology, gastrointestinal and neurology. In addition, the Company remains open to considering the in-licensing of products in other specialty areas where the Company believes there may be an attractive market opportunity. The in-licensing strategy represents future growth opportunities as the Company launches innovative and unique treatments across its markets.

(In thousands of Canadian dollars, except for share and per share amounts)

The following are examples of the execution of this strategy related to products added to Knight's portfolio through in-licensing:

Date	Product	Territory
Q4-16	Movantik (naloxegol)	Canada
Q1-18	Ibsrela® (tenapanor)	Canada
Q3-18	Imvexxy® (estradiol vaginal inserts)	Canada
Q3-18	Bijuva® (estradiol and progesterone)	Canada
Q1-19	Nerlynx® (neratinib)	Canada
Q1-20	Trelstar® (tripotorelin)	Canada
Q3-21	Minjuvi® (tafasitamab)	LATAM
Q3-21	Pemazyre® (pemigatinib)	LATAM
Q2-22	Tavalisse® (fostamatinib)	LATAM
Q2-22	Akynzeo® (netupitant/palonosetron/fosnetupitant/palonosetron)	Canada and select LATAM territories
Q2-22	Aloxi® (palonosetron)	Canada
Q4-23	Qelbree™ (viloxazine)	Canada
Q1-24	IPX203 (carbidopa and levodopa extended-release capsules)	Canada and LATAM
Q2-24	Jornay PM™ (methylphenidate extended-release capsules)	Canada and LATAM

3. Development & In-licensing of branded generic products

The Company's branded generic development efforts include the internal development of branded generics for Argentina and other LATAM markets (excluding Brazil and Mexico) and the in-licensing of branded generics for LATAM markets including Brazil and Mexico. The Company continues to maintain a targeted internal development effort to develop and manufacture branded generics products for launch in Argentina and eventually in certain markets in Latin America. In addition to internal development, the growth of the branded generic portfolio is supplemented through in-licensing of additional molecules. This strategy complements the in-house development efforts by providing access to the two largest pharmaceutical markets in Latin America, namely Brazil and Mexico. In addition, it allows access to branded generics products that cannot be developed or manufactured in-house by the Company.

The following are examples of the execution of this strategy via in-licensing:

Date	Molecule	Territory
Q4-21	C401 (Neurology)	Select LATAM territories
Q4-21	H401 (Oncology / Hematology)	Select LATAM territories
Q2-22	C402/403 (Neurology)	Select LATAM territories
Q3-23	H402 (Oncology / Hematology)	Brazil and Colombia

(In thousands of Canadian dollars, except for share and per share amounts)

Prescription Pharmaceutical Products

The following summarizes certain products from Knight's product portfolio.

PRODUCT	INDICATION[1,2]	TERRITORY[3]					PARTNER
		Canada	Brazil	Argentina	Colombia	Mexico	
Oncology/Hematology							
Minjuvi®	Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)	— [4]	Q1-24	Submitted	Submitted	Approved	Incyte
Pemazyre®	Metastatic cholangiocarcinoma	— [4]	Submitted	Submitted	Submitted	Submitted	Incyte
Akynzeo®	Prevention of chemotherapy-induced acute and delayed nausea and vomiting	Q4-22	Q3-22	Q3-22	— [4]	— [4]	Helsinn
Aloxi®	Prevention of acute nausea and vomiting associated with moderately and highly emetogenic cancer chemotherapy	Q4-22	— [4]	— [4]	— [4]	— [4]	Helsinn
Tavalisse®	Treatment of chronic immune thrombocytopenia	— [4]	Submitted	Pre-registration	Submitted	Submitted	Rigel
Trelstar®	Advanced prostate cancer	Q2-20	— [4]	— [4]	— [4]	— [4]	Debiopharm
Vidaza®	Myelodysplastic syndrome	— [4]	Q2-10	— [4]	— [4]	— [4]	BMS
Abraxane®	Metastatic pancreatic cancer	— [4]	Q4-17	— [4]	— [4]	— [4]	BMS
Halaven®	Metastatic breast cancer and soft tissue sarcoma	— [4]	Q4-17	Q4-19	Q2-22	— [4]	Eisai
Lenvima®	Differentiated thyroid cancer and unresectable hepatocellular carcinoma	— [4]	Q4-17		Q1-22	— [4]	Eisai
Lenvima®	Advanced renal cell cancer	— [4]	Q4-17			— [4]	Eisai
BGx							
Ladevina® (lenalidomide)	Multiple myeloma; myelodysplastic syndrome			2011	Q3-19		Own
Ladevina® (lenalidomide)	Mantle Cell Lymphoma; follicular lymphoma			2011			Own
Zyvalix® (abiraterone)	Metastatic prostate cancer			2014	Q2-18		Own
Karfib® (carfilzomib)	Relapsed or refractory multiple myeloma			Q4-19	Approved		Own
Leprid® (leuprolide)	Palliative treatment of advanced prostate cancer			2007			Own
Rembre® (dasatinib)	Chronic myeloid leukemia			2013	Q1-22		Own
Palbocil®, Bapocil® (palbociclib)	Breast cancer			Q1-23	Submitted		Own
Xetrane® (pomalidomide)	Multiple myeloma			Q2-19	Submitted		Own
Xetrane® (pomalidomide)	AIDS-related Kaposi sarcoma			Q2-22			Own

[1] *The products listed as "Pre-registration" have not yet been submitted for regulatory review and products in "Submitted" are currently under regulatory review. The indication for all products classified as "Pre-registration" or "Submitted" is the anticipated indication upon regulatory approval.*

[2] *The products listed as "Approved" have been approved by regulatory authorities but not yet commercially launched.*

[3] *The products with an associated date are currently marketed by Knight in the respective territory. The information provided represents the date when the product was launched by Knight or when it was acquired or in-licensed by Knight if such products had existing sales.*

[4] *Knight does not have the commercial rights in these territories.*

(In thousands of Canadian dollars, except for share and per share amounts)

PRODUCT	INDICATION	TERRITORY					PARTNER
		Canada	Brazil	Argentina	Colombia	Mexico	
Infectious Diseases							
Ambisome®	Invasive fungal infection	— [4]	1997	— [4]	— [4]	— [4]	Gilead
Cresemba®	Invasive fungal infection	— [4]	Q2-20	Q3-19	Q3-19	Q2-19	Basilea
Impavido®	Leishmaniasis						Own
BGx							
Dolufevir® (dolutegravir)	HIV infection			Q2-21			Own
Other Specialty							
Exelon®	Symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease	Q2-21	Q2-21	Q2-21	Q2-21	Q2-21	Own
Ibsrela®	IBS-C	Q1-21	— [4]	— [4]	— [4]	— [4]	Ardelyx
Salofalk®	Ulcerative colitis	— [4]	— [4]	2007	Pre-2019	— [4]	Dr. Falk
Ursofalk®	Primary biliary cirrhosis	— [4]	— [4]	2007	Pre-2019	— [4]	Dr. Falk
Imvexxy®	Moderate-to-severe dyspareunia	Q1-24	— [4]	— [4]	— [4]	— [4]	TXMD
Bijuva®	Moderate-to-severe vasomotor symptoms due to menopause	Q1-24	— [4]	— [4]	— [4]	— [4]	TXMD
BGx							
Fibridoner® (pirfenidone)	Idiopathic pulmonary fibrosis			2017			Own

			Change				Change	
IQVIA sales in Canada	**Q3-24**	Q3-23	**$**	**%**	**YTD-24**	YTD-23	**$**	**%**
Akynzeo®	2,935	2,055	880	43%	7,968	5,746	2,222	39%
Trelstar®	2,001	1,888	113	6%	6,169	5,264	905	17%
Ibsrela®	406	294	112	38%	1,135	818	317	39%
Imvexxy®	692	—	—	—%	1,305	—	—	—%
Total	6,034	4,237	1,797	42%	16,577	11,828	4,749	40%

(In thousands of Canadian dollars, except for share and per share amounts)

PIPELINE

The Company believes that its pipeline of innovative and branded generics products will drive future growth but there is no certainty that any of these molecules will be launched due to inherent development, regulatory, legal and commercial risks in launching a pharmaceutical product. The Company's pipeline of undisclosed molecules which could potentially be launched as branded generic products in the future includes internally developed and in-licensed products in the following stages:

1. **Development**: Formulation or clinical development on-going;
2. **Submitted**: Molecule has been submitted by the Company to a health authority agency for approval; and
3. **Approved**: Molecule has obtained regulatory approval, but launch is pending additional local technical requirements.

Pipeline and products in early launch stage

The Company expects that its pipeline and products in early launch stage could achieve total revenues over $150,000 in combined revenues in their peak years. The products in early launch stage are within three years from the commercial launch date on a country-by-country basis.

PRODUCT	INDICATION OR THERAPEUTIC AREA	TERRITORY					EXPECTED LAUNCH YEAR
		Canada	Brazil	Argentina	Colombia	Mexico	
Oncology/Hematology							
Minjuvi®	Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)	— [2]	Q1-24	Submitted	Submitted	Approved	2025 -2026
Pemazyre®	Metastatic cholangiocarcinoma	— [2]	Submitted	Submitted	Submitted	Submitted	2025-2026
Tavalisse®	Treatment of chronic immune thrombocytopenia	— [2]	Submitted	Pre-registration	Submitted	Submitted	2025-2026
Bapocil® [1]	Breast Cancer				Submitted		2025
Xetrane® [1]	Multiple myeloma				Submitted		2025
Rembre® [1]	Chronic myeloid leukemia				Q1-22		—
O501 [1]	Oncology/Hematology			Submitted			2025
O502 [1]	Oncology/Hematology			Submitted			2025
H402	Oncology/Hematology		Development		Development		2028-2029
Other Specialty							
Imvexxy®	Moderate-to-severe dyspareunia	Q1-24	— [2]	— [2]	— [2]	— [2]	—
Bijuva®	Moderate-to-severe vasomotor symptoms due to menopause	Q1-24	— [2]	— [2]	— [2]	— [2]	—
IPX203	Parkinson's disease	Pre-registration	Pre-registration	Pre-registration	Pre-registration	Pre-registration	2027-2028
Qelbree™	Attention-Deficit Hyperactivity Disorder (ADHD)	Pre-registration	— [2]	— [2]	— [2]	— [2]	2026-2027
Jornay PM™	Attention-Deficit Hyperactivity Disorder (ADHD)	Submitted	Pre-registration			Pre-registration	2025-2028
C401 (Neurology)	Other Specialty				Submitted	— [2]	2025-2026
C402/403 (Neurology)	Other Specialty	— [2]	Submitted		Development	Pre-registration	2026-2027

[1] Products developed by Knight's internal BGx capabilities in Argentina. Unless otherwise noted in above table, these products are marketed in Argentina.
[2] Knight does not have the commercial rights in these territories.

Product Updates

Expansion of Product Pipeline	
Q1-24	• In-licensed IPX203 (carbidopa and levodopa extended-release capsules) for Canada and Latin America
Q2-24	• Entered into an exclusive supply and distribution agreement for Jornay PM™ (methylphenidate HCl extended-release capsules) for Canada and Latin America.
Regulatory Submission	
Q1-24	• Submitted fostamatinib for ANVISA approval in Brazil.
Regulatory Approval	
Q1-24	• Obtained regulatory approval for Karfib® (carfilzomib) in Colombia.
Q4-24	• Obtained regulatory approval for Minjuvi® (tafasitamab) in Mexico.
Product Launches	
Q1-24	• Launched Minjuvi® (tafasitamab) in Brazil. • Launched Imvexxy® (estradiol vaginal inserts) and Bijuva® (estradiol and progesterone) in Canada.

IPX203

In Q1-24, Knight in-licensed IPX203 for Canada and Latin America. IPX203 is a novel, oral formulation of carbidopa/levodopa extended-release capsules designed for the treatment of Parkinson's disease. IPX203 contains immediate-release (IR) granules and extended-release (ER) coated beads. The IR granules consist of CD and LD, with a disintegrant polymer to allow for rapid dissolution. The ER beads consist of LD, coated with a sustained release polymer to allow for slow release of the drug, a mucoadhesive polymer to keep the granules adhered to the area of absorption longer, and an enteric coating to prevent the granules from disintegrating prematurely in the stomach. IPX203 was studied in the RISE-PD clinical study which was a 20-week, randomized, double-blind, double-dummy, active-controlled, phase 3 clinical trial with 630 patients. The RISE-PD study met its primary and secondary endpoints and showed that treatment with IPX203 demonstrated statistically significant improvement in daily "Good On" time with fewer doses of IPX203 compared with immediate-release carbidopa-levodopa (least squares mean, 0.53 hours; 95% CI, 0.09-0.97), with IPX203 dosed a mean three times per day vs 5 times per day for immediate-release carbidopa-levodopa[1]. IPX203 is expected to compete in a market size of over $50,000 in Canada and over $120,000 in Brazil, of which the controlled release portion of the market is $15,000 in each country, according to IQVIA. In September 2024, Knight's partner Amneal Pharmaceuticals, Inc., announced the launch of CREXONT®, a novel oral formulation of carbidopa/levodopa in pharmacies across the U.S.

Jornay PM™

In Q2-24, Knight obtained the rights to seek regulatory approval and commercialize Jornay PM™ in Canada and Latin America. Jornay PM™, is an extended-release formulation of methylphenidate, a stimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). Jornay PM™ is the first and only evening-dosed methylphenidate product commercially available in the United States to treat ADHD in patients 6 years of age and older. Jornay PM™ consists of microbeads with a delayed-release layer and an extended-release layer. The first layer delays the release of the active ingredient until morning while the extended-release layer controls the release of the active ingredient from the early morning and throughout the day. This unique formulation provides a pharmacokinetic profile that allows ADHD symptom control from the time patients wake up until they go to bed. Jornay PM™ was studied in two randomized, double-blind, placebo-controlled, phase 3 clinical trials[2,3]. Both studies met their primary and key secondary endpoints demonstrating a statistically significant and clinically meaningful improvement in ADHD symptoms upon awakening, through the afternoon, and into the evening. Jornay PM™ was submitted for approval in Canada in November 2023. According to IQVIA for the twelve months ended June 30, 2023, the Canadian ADHD market totaled approximately $1.1 billion with methylphenidate representing for $460,000 and growing at over 16% CAGR over the last four years.

Minjuvi®

In Q4-24, Knight obtained regulatory approval by COFEPRIS, the Mexican health regulatory agency, for Minjuvi® (tafasitamab) in combination with lenalidomide followed by Minjuvi® monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who are not eligible for autologous stem cell transplantation (ASCT). The Company expects to launch Minjuvi® in Mexico in the first half of 2025.

In Q3-24, Minjuvi® was submitted to ANS for private reimbursement in Brazil. Earlier this year, Minjuvi® was launched in Brazil.

---

[1] *Hauser RA et al. JAMA Neurol. 2023 Oct 1;80(10):1062-1069.*

[2] *Childress, A. C., Cutler, A. J., Marraffino, A., McDonnell, M. A., Turnbow, J. M., Brams, M., DeSousa, N. J., Incledon, B., Sallee, F. R., & Wigal, S. B. (2020). A randomized, double-blind, placebo-controlled study of HLD200, a delayed-release and extended-release methylphenidate, in children with attention-deficit/hyperactivity disorder: An evaluation of safety and efficacy throughout the day and across settings. Journal of Child and Adolescent Psychopharmacology, 30(1), 2–14. https://doi.org/10.1089/cap.2019.0070*

[3] *Pliszka, S. R., Wilens, T. E., Bostrom, S., Arnold, V. K., Marraffino, A., Cutler, A. J., López, F. A., DeSousa, N. J., Sallee, F. R., Incledon, B., & Newcorn, J. H. (2017). Efficacy and safety of HLD200, delayed-release and extended-release methylphenidate, in children with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 27(6), 474–482. https://doi.org/10.1089/cap.2017.0084*

(In thousands of Canadian dollars, except for share and per share amounts)

Lenvima®

During 2023, two companies received ANVISA's approval for generic lenvatinib in Brazil. During 2024, both of those companies received the approval for a branded generic lenvatinib. Additionally, in Q3-24, a competitor received the approval of a generic lenvatinib in Chile.

In Q3-24, a competitor in Brazil launched both a branded generic and a generic of Lenvima®. Knight and Eisai are collaborating to defend Lenvima's® market exclusivity in Brazil. While we continue to continue to challenge the generic entrants, the introduction of generics and branded generics will increase competitive pressures and negatively impact future sales and margins of Lenvima® in Brazil.

Section 10 – Strategic Lending and Investments

Strategic Lending

Knight finances other life sciences companies in all geographic markets with the goal of strengthening relationships in the life sciences industry and securing product distribution rights for Canada and select international markets. To date, the strategic lending portfolio has led to the acquisition of Neuragen and the in-licensing of several products from Profound and Triumvira. As of the date hereof, Knight has two secured loans outstanding to life sciences companies as outlined in the table below.

			Nominal loan balance as at September 30, 2024			
Entity	**Maturity date**	**Interest rate**	**In Source Currency**		**In CAD[1]**	
Synergy	Mar 31, 2026	12%	US $	7,320	$	9,881
Other strategic loans	Apr 15, 2025	10%	US $	2,771	$	3,741
Total			**US $**	**10,091**	**$**	**13,622**

[1] *Converted at the Bank of Canada closing exchange rates on September 30, 2024.*

Fund Investments

Knight invests in life sciences venture capital funds in which the Company earns a return similar to any other limited partner in the fund and may receive preferential access to innovative healthcare products from around the world for Canada and select international markets. Knight has remaining commitments to invest in life science venture capital funds of $6,235 as at September 30, 2024. Knight does not expect to invest in additional venture capital funds.

As at	**September 30, 2024**
FMV of funds by expected exit date	**$**
1-3 years	11,490
4-5 years	52,559
5+ years	25,876
Total	**89,925**

(In thousands of Canadian dollars, except for share and per share amounts)

As at	September 30, 2024	December 31, 2023
Inception to Date:		
Capital calls	164,558	159,781
Distributions received	(134,944)	(129,326)
Realized gain	74,126	70,062
Unrealized gain (loss)	(13,815)	8,205
Funds FMV	**89,925**	**108,722**
TVPI[1]	**1.37x**	**1.49x**
Contingent gains[2]	12,821	12,914
TVPI[1] considering contingent gains[2]	**1.44x**	**1.57x**

[1] *TVPI represents total value to paid-in ratio which is calculated as distributions received from the strategic funds and the residual value not yet realized relative to the contributed paid-in capital.*
[2] *Knight does not record certain contingent gains related to the investments in the strategic funds until it is probable that such gains will be realized. Contingent gains on the investments in the strategic funds include milestones payments to the strategic funds based upon achieving certain events such as clinical success of a trial, regulatory approval of a drug or certain sales-based event.*

Equity Investments

Under IFRS 9, the Company has designated the following strategic investments as equity investments measured at FVOCI.

	September 30, 2024		December 31, 2023	
	Number of common shares owned	FV $	Number of common shares owned	FV $
Crescita	**1,935,489**	**1,161**	1,935,489	948
Synergy[1]	**1,482,844**	**14,412**	17,645,812	—
Total		**15,573**		948

[1] The decrease in the number of shares of Synergy common stock held by Knight is due to a reverse stock split of 1-for-11.9 in the Synergy common stock, which was effected by Synergy on September 11, 2024.

On October 23, 2024 Synergy completed an IPO of 1.15 million shares of common stock on NASDAQ that were issued by Synergy at a price per share of US $9 ("Synergy's IPO"). As at September 30, 2024, prior to Synergy's IPO, the Company owned 1,482,844 common stock or approximately 19.6% of Synergy's outstanding common stock, received as consideration for the Company's strategic lending transactions with Synergy. Subsequent to Synergy's IPO, Knight's ownership of Synergy common stock was diluted to approximately 17%. The Synergy common shares held by Knight are subject to a 180-day post IPO lock-up period and are also subject to certain restrictions imposed under U.S. federal securities laws.

For the quarter ended September 30, 2024, the shares of Synergy common stock held by Knight were recorded at their fair value based on the Synergy's IPO price discounted by an illiquidity factor resulting in an unrealized gain of $14,412 (US$ 10,676) recorded in other comprehensive income. The Synergy shares held by Knight are classified as a level 2 equity investment measured at FVOCI . Furthermore, due to Synergy's IPO the day 1 gain of $5,081 (US$3,764) was de-recognized.

Section 11 – Risk Management

An investor should carefully consider the information contained in this MD&A, in addition to the risk factors discussed in the Company's AIF under the heading "Risk Factors", which section is hereby incorporated herein by reference. The disclosures in this MD&A are subject to the risk factors outlined in the AIF. Additional risks and uncertainties not presently known to the Company or that the Company believes to be immaterial may also adversely affect the Company's business. If any one or more of the risks occur as outlined in the AIF, the Company's business, financial condition and results of operations could be seriously harmed. Further, if the Company fails to meet the expectations of the public market in any given period, the market price of the Company's common shares could decline. Before making an investment decision, each prospective investor should carefully consider the risk factors included in the AIF and other public documents.

For a detailed discussion of additional risk factors, please refer to the Company's latest AIF on SEDAR+ at www.sedarplus.ca.

Section 12 – Commitments

In the normal course of business, the Company secures development, sales, marketing and distribution rights to innovative drug products requiring royalties or product payments. These payments are considered normal operating commitments and as such are not included herein. The Company has entered into various agreements which include contractual commitments extending beyond the current year. These commitments are classified into three major categories: fund commitments, milestone and purchase commitments. The commitments of the Company as at September 30, 2024 are as follows:

[i] Fund commitments

As at September 30, 2024, under the terms of the Company's agreements with life sciences venture capital funds, $6,235 may be called over the life of the funds.

As at November 6, 2024, $6,238 remains to be called by life science venture capital funds.

[ii] Milestones and purchase commitments

Under certain agreements, Knight may have to pay additional consideration should the Company achieve certain sales volumes or if certain milestones are met, such as regulatory approval. Milestone that the Company expects will be achieved have been recorded as a liability in *Other Balances Payable*.

The Company may have to pay up to $453,267 including $158,532 [US $117,440], $160,617 [CHF 100,160] and $3,834 [EUR 2,543] upon achieving certain sales volumes, regulatory or other milestones related to specific products. These milestone are not currently expected to be achieved in the future.

As at November 6, 2024, the Company may have to pay up to $458,716 upon achieving certain sales volumes, regulatory or other milestones related to specific products.

In addition, Knight has a commitment to purchase up to $8,362 [CHF 4,014 and EUR 1,277], of inventory for pharmaceutical products during the five-year period after their respective commercial launch.

(In thousands of Canadian dollars, except for share and per share amounts)

For products that are currently launched, the Company has committed to inventory purchases of $131,946 [BRL 142,600, US $46,490, EUR 10,185 and CHF 11,500], which will be purchased over the next 7 years.

	$
2024	6,000
2025	56,027
2026	22,210
2027	20,411
2028	11,772
2029 and beyond	15,526
Total	**131,946**

As at November 6, 2024, the Company has a commitment to purchase up to $8,390 of inventory for pharmaceutical products during the five-year period after their respective commercial launch and has a commitment to purchase $132,939 for products that are currently launched.

Section 13 – Outstanding Share Data

The table below summarizes the share data:

As at	October 31, 2024	September 30, 2024
Common Shares	100,802,766	100,975,966
Stock Options	5,121,259	5,121,259
RSUs	371,182	371,182
PSUs	965,192	965,192
DSUs	196,513	196,513
Warrants	174,228	174,228

On July 11, 2024, the Company announced that the Toronto Stock Exchange approved its notice of intention to launch a NCIB ("2024 NCIB"). Under the terms of the 2024 NCIB, the Company may purchase for cancellation up to 5,312,846 common shares of the Company which represented 10% of its public float as at June 30, 2024. The 2024 NCIB commenced on July 15, 2024 and will end on the earlier of July 14, 2025 or when the Company completes its maximum purchases under the NCIB. Furthermore, the Company entered into an agreement with a broker to facilitate purchases of its common shares under the NCIB. Under Knight's automatic share purchase plan, the broker may purchase common shares which would ordinarily not be permitted due to regulatory restrictions or self-imposed blackout periods.

During the three and nine-month periods ended September 30, 2024, the Company purchased 437,500 and 643,161 (2023: 2,158,091 and 7,277,016, respectively) common shares, at an average price of $5.65 and $5.78, respectively (2023: $4.55 and $4.73, respectively) for aggregate cash consideration of $2,474 and $3,716, respectively (2023: $9,833 and $34,396, respectively).

Subsequent to quarter-end up to October 31, 2024, the Company purchased an additional 190,000 common shares at an average purchase price of $5.66 for an aggregate cash consideration of $1,076.

Section 14 – Significant Accounting Estimates and Assumptions

The preparation of the Company's interim condensed consolidated financial statements requires management to make judgments and estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts or revenues and expenses during the reporting period. Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. Our significant accounting estimates and assumptions are reported in note 3 of our 2023 Annual Financial Statements.

Future Changes and Amendments to Accounting Standards

IFRS 18 Presentation and Disclosure in the Financial Statements
The IASB issued IFRS 18 *Presentation and Disclosure in the Financial Statements,* which sets out requirements and guidance on presentation and disclosure in financial statements, including:

- presentation in income statement of income and expenses within five defined categories: operating, investing, financing, income taxes, and discontinued operations
- presentation in the income statements of new defined subtotals for operating profit and profit before financing and income taxes
- enhanced guidance on aggregation and disaggregation of information and whether to provide information in the financial statements or in the notes
- disclosure of specified expenses by nature
- disclosure of explanations of management-defined performance measures

IFRS 18 will replace IAS 1 *Presentation of Financial Statements* but carries forward many requirements from IAS 1 without any change. The standard is effective for the annual reporting periods beginning on or after January 1, 2027, with early application permitted. The Company is currently assessing the impact of this new standard on its consolidated financial statements.

Amendments to IFRS 9 *Financial Instruments* and IFRS 7 *Financial Instruments*
The IASB issued amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments. The amendments clarify the date of recognition and derecognition of some financial assets and liabilities, introduces an accounting policy option for financial liabilities settled using an electronic payment system if certain conditions are met and adds new disclosure requirements for financial instruments with contractual terms that reference a contingent event and equity instruments classified at fair value through other comprehensive income.

The amendments to are effective for annual reporting periods beginning on or after January 1, 2026, with early application permitted. The Company is currently assessing the impact of these amendments on its consolidated financial statements.

Section 15 – Non-GAAP measures

The Company discloses non-GAAP measures and ratios that do not have standardized meanings prescribed by IFRS. The Company believes that shareholders, investment analysts and other readers find such measures helpful in understanding the Company's financial performance. Non-GAAP financial measures and adjusted EBITDA per share ratio do not have any standardized meaning prescribed by IFRS and may not have been calculated in the same way as similarly named financial measures presented by other companies.

The Company uses the following non-GAAP measures.

[i] Revenues and Financial results excluding the impact of hyperinflation under IAS 29

The Company applies IAS 29, Financial Reporting in Hyperinflation Economies, as the Company's Argentine subsidiaries used the Argentine Peso as their functional currency. IAS 29 requires that the financial statements of an entity whose functional currency is the currency of a hyperinflationary economy be adjusted based on an appropriate general price index to express the effects of inflation.

Revenues and financial results under IFRS are adjusted to remove the impact of hyperinflation under IAS 29. The impact of hyperinflation under IAS 29 is calculated by applying an appropriate general price index to express the effects of inflation. After applying the effects of translation, the statement of income is converted using the closing foreign exchange rate of the month.

Revenues and financial results excluding the impact of hyperinflation under IAS 29 allow results to be viewed without the impact of IAS 29 thereby facilitating the comparison of results period over period. The presentation of revenues and financial results excluding the impact of hyperinflation under IAS 29 is considered to be a non-GAAP measure and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies.

(In thousands of Canadian dollars, except for share and per share amounts)

The following tables are reconciliations of financial results under IFRS to financial results excluding the impact of hyperinflation under IAS 29.

	Q3-24			YTD-24		
	Reported under IFRS	**IAS 29 Adjustment**	**Excluding the Impact of IAS 29**	**Reported under IFRS**	**IAS 29 Adjustment**	**Excluding the Impact of IAS 29**
Revenues	**92,263**	**(833)**	**91,430**	**274,440**	**(3,094)**	**271,346**
Cost of goods sold	**47,246**	**988**	**48,234**	**140,387**	**1,786**	**142,173**
Gross margin	**45,017**	**(1,821)**	**43,196**	**134,053**	**(4,880)**	**129,173**
Gross margin (%)	***49%***		***47%***	***49%***		***48%***
Expenses						
Selling and marketing	**13,372**	**(175)**	**13,197**	**39,285**	**(627)**	**38,658**
General and administrative	**12,110**	**(188)**	**11,922**	**34,747**	**(1,036)**	**33,711**
Research and development	**5,153**	**219**	**5,372**	**15,939**	**(150)**	**15,789**
Amortization of intangible assets	**11,179**	**(18)**	**11,161**	**33,725**	**(18)**	**33,707**
Operating income	**3,203**	**(1,659)**	**1,544**	**10,357**	**(3,049)**	**7,308**

	Q3-23			YTD-23		
	Reported under IFRS	IAS 29 Adjustment	Excluding the Impact of IAS 29	Reported under IFRS	IAS 29 Adjustment	Excluding the Impact of IAS 29
Revenues	81,500	169	81,669	254,002	734	254,736
Cost of goods sold	41,318	(1,770)	39,548	135,565	(4,580)	130,985
Gross margin	40,182	1,939	42,121	118,437	5,314	123,751
Gross margin (%)	*49%*		*52 %*	*47%*		*49 %*
Expenses						
Selling and marketing	11,924	13	11,937	35,463	172	35,635
General and administrative	11,080	(71)	11,009	29,305	(221)	29,084
Research and development	4,768	(117)	4,651	13,291	85	13,376
Amortization of intangible assets	11,480	(5)	11,475	33,925	(136)	33,789
Operating income	930	2,119	3,049	6,453	5,414	11,867

[ii] Revenues and Financial results at constant currency

Revenues and financial results at constant currency are obtained by translating the prior period revenues and financial results from the functional currencies to CAD using the conversion rates in effect during the current period. Furthermore, with respect to Argentina, the Company excludes the impact of hyperinflation and translates the revenues and results at the average exchange rate in effect for each of the periods.

Revenues and financial results at constant currency allow results to be viewed without the impact of fluctuations in foreign currency exchange rates thereby facilitating the comparison of results period over period. The presentation of revenues and financial results under constant currency is considered to be a non-GAAP measure and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies.

(In thousands of Canadian dollars, except for share and per share amounts)

The following tables are reconciliations of financial results under IFRS to financial results and financial results at constant currency.

	Q3-23			YTD-23		
	Excluding the impact of IAS 29[1]	Constant Currency Adjustment	Constant Currency	Excluding the impact of IAS 29[1]	Constant Currency Adjustment	Constant Currency
Revenues	81,669	(4,040)	77,629	254,736	(448)	254,288
Cost of goods sold	39,548	(2,455)	37,093	130,985	(1,002)	129,983
Gross margin	42,121	(1,585)	40,536	123,751	554	124,305
Gross margin (%)	*52%*		*52%*	*49%*		*49%*
Expenses						
Selling and marketing	11,937	(559)	11,378	35,635	(354)	35,281
General and administrative	11,009	(249)	10,760	29,084	252	29,336
Research and development	4,651	(111)	4,540	13,376	(15)	13,361
Amortization of intangible assets	11,475	129	11,604	33,789	256	34,045
Operating income	3,049	(795)	2,254	11,867	415	12,282

[1] *Refer to Subsection - [i] Revenues and Financial results excluding the impact of hyperinflation under IAS 29 for additional details.*

[iii] EBITDA

EBITDA is defined as operating income or loss adjusted to exclude amortization and impairment of intangible assets, depreciation, purchase price allocation accounting adjustments, and the impact of IAS 29 (accounting under hyperinflation) but to include costs related to leases.

EBITDA allows results to be viewed without the impact of amortization and impairment of intangible assets, depreciation, purchase price allocation accounting adjustments, and the impact of IAS 29 (accounting under hyperinflation) but to include costs related to leases fluctuations in foreign currency exchange rates thereby facilitating the comparison of results period over period. The presentation of EBITDA is considered to be a non-GAAP measure and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies.

[iv] Adjusted EBITDA

Adjusted EBITDA is defined as EBITDA adjusted for acquisition costs and non-recurring expenses. Adjusted EBITDA allows results to be viewed without the impact of amortization and impairment of intangible assets, depreciation, purchase price allocation accounting adjustments, and the impact of IAS 29 (accounting under hyperinflation), acquisition costs and non-recurring expenses but to include costs related to leases fluctuations in foreign currency exchange rates thereby facilitating the comparison of results period over period. The presentation of adjusted EBITDA is considered to be a non-GAAP measure and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies.

The following table is a reconciliation of operating income (loss) to EBITDA and adjusted EBITDA.

	Q3-24	Q3-23	YTD-24	YTD-23
Operating income	**3,203**	930	**10,357**	6,453
Adjustments to operating income:				
Amortization of intangible assets	**11,179**	11,480	**33,725**	33,925
Depreciation of property, plant and equipment and ROU assets	**2,210**	2,218	**5,414**	5,014
Lease costs (IFRS 16 adjustment)	**(997)**	(779)	**(2,861)**	(2,146)
Impact of IAS 29	**(2,265)**	1,663	**(4,075)**	4,772
EBITDA	**13,330**	15,512	**42,560**	48,018
Acquisition costs	**18**	—	**121**	—
Other non-recurring expenses	**106**	—	**106**	—
Adjusted EBITDA	**13,454**	15,512	**42,787**	48,018

[v] Adjusted EBITDA per share

Adjusted EBITDA per share is defined as Adjusted EBITDA over number of common shares outstanding at the end of the respective period. The presentation of adjusted EBITDA per share is considered to be a non-GAAP ratio and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies.

The following table calculates adjusted EBITDA per share as follows:

	Q3-24	Q3-23	YTD-24	YTD-23
Adjusted EBITDA	**13,454**	15,512	**42,787**	48,018
Adjusted EBITDA per common share	**0.13**	0.15	**0.42**	0.46
Number of common shares outstanding at period end (in thousands)	**100,976**	105,045	**100,976**	105,045

Section 16 – Disclosure Controls and Procedures

The Company is committed to providing timely, accurate and balanced disclosure of all material information about the Company and to providing fair and equal access to such information. Management is responsible for establishing and maintaining its DC&P to ensure that information used internally and disclosed externally is complete and reliable. Due to the inherent limitations in all control systems, an evaluation of controls can provide only reasonable, not absolute assurance, that all control issues and instances of fraud or error, if any, within the Company have been detected. Management continues to evolve and enhance its system of controls and procedures.

Section 17 – Internal Control Over Financial Reporting (ICFR)

The Company's management is responsible for establishing and maintaining adequate Internal Control Over Financial Reporting (ICFR). The Company has designed ICFR to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with IFRS.

All control systems, no matter how well designed, have inherent limitations, including the possibility of human error and the circumvention or overriding of the controls or procedures. As a result, there is no certainty that our DC&P or ICFR will prevent all errors or all fraud.

During the quarter ended September 30, 2024, there was no significant changes in our internal control over financial reporting that materially affected or is reasonably likely to materially affect the Company's internal controls over financial reporting.

(In thousands of Canadian dollars, except for share and per share amounts)

GLOSSARY OF ABBREVIATIONS

Abbreviation	Calendar
Q3-24	Third quarter of 2024
Q2-24	Second quarter of 2024
Q1-24	First quarter of 2024
Q4-23	Fourth quarter of 2023
Q3-23	Third quarter of 2023
Q2-23	Second quarter of 2023
Q1-23	First quarter of 2023
Q4-22	Fourth quarter of 2022
Q3-22	Third quarter of 2022

Abbreviation	Company
Advaxis	Advaxis Pharmaceuticals Inc.
Ardelyx	Ardelyx, Inc.
Basilea	Basilea Pharmaceuticals Ltd.
BMS	Bristol-Myers Squibb
GBT	Biotoscana Investments S.A.
Helsinn	Helsinn Healthcare SA
IFC	International Finance Corporation
Incyte	Incyte Biosciences International Sàrl
IQVIA	IQVIA Incorporated, a leading pharmaceutical market research organization
Knight or the Company	Knight Therapeutics Inc.
M8	M8 Pharmaceuticals, Inc.
Novartis	Novartis AG, Novartis Pharma AG or their affiliates
Profound	Profound Medical Inc.
Rigel	Rigel Pharmaceuticals, Inc.
Synergy	Synergy CHC Corp.
Triumvira	Triumvira Immunologics Inc.
TXMD	TherapeuticsMD, Inc.

Abbreviation	Financial
AIF	Annual information form
Annual Financial Statements	Audited annual consolidated financial statements
ARS	Argentine Peso
BRL	Brazilian Real
C$ or $ or CAD	Canadian Dollar
CHF	Swiss Franc
CLP	Chilean Peso
COP	Colombian Peso
DC&P	Disclosure Controls and Procedures
DSU	Deferred share units
EPS	Earnings per share to common shareholders
EUR	Euro
FMV	Fair market value
FVTPL	Fair value through profit or loss
GAAP	Generally accepted accounting principles
G&A	General and administrative
ICFR	Internal control over financial reporting
IFRS	International Financial Reporting Standards
MXN	Mexican Peso
PSU	Performance share units
R&D	Research and development
ROU	Right-of-use
RSU	Restricted share units
S&M	Selling and marketing
US$/USD	U.S. Dollar

Abbreviation	Territory
CAN	Canada
LATAM	Latin America
U.S.	United States of America

Abbreviation	Other
ANS	Brazilian Regulatory Agency for Private Health Insurance and Plans
ANVISA	Brazilian Health Regulatory Agency
BGx	Branded Generic Pharmaceutical Product
CEO	Chief Executive Officer
ESPP	Employee Share Purchase Plan
HCC	Unresectable hepatocellular carcinoma
HCV	Human hepatitis virus infection
HIV	Human immunodeficiency virus infection
IBS-C	Irritable Bowel Syndrome with Constipation
IPO	Initial Public Offering
MOH	Ministry of Health of Brazil
NCIB	Normal Course Issuer Bid
NIHB	Non-Insured Health Benefits for First Nations and Inuit Program